Shots:

• The discontinuation is based on pre-planned interim analyses of P-III studies assessing Pimodivir + SOC vs SOC as monothx. in hospitalized & non-hospitalized patients with influenza A
• The therapy is unlikely to add benefits in hospitalized patients with influenza A. The company will halt both the studies- after consulting with BARDA
• In 2014- Janssen signed an exclusive license agreement with Vertex for the global development- manufacturing- and commercialization of pimodivir

­ Ref: Janssen | Image: Janssen